Intuitive Surgical · ISRG

[1] Intuitive 2026年第二季度财报

发布日期：2026-07-16

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/01_source.txt

Second quarter 2026 revenue was $2.89 billion, an increase of 19% compared with $2.44 billion in the second quarter of 2025. The higher second quarter revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue, and an increase in the installed base of da Vinci and Ion systems.

[2] Intuitive 2025 Q4财报

发布日期：2026-01-22

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/02_source.txt

| Total revenue | | 2,866.2 | | | | 2,505.1 | | | | 2,413.5 | |

[3] Intuitive 2025Q3财报

发布日期：2025-10-21

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/04_source.txt

Third quarter 2025 revenue was $2.51 billion, an increase of 23% compared with $2.04 billion in the third quarter of 2024. The higher third quarter revenue was driven by growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of systems.

[4] Intuitive 2026Q1财报

发布日期：2026-04-21

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/05_source.txt

- First quarter 2026 revenue of $2.77 billion increased 23%, compared with $2.25 billion in the first quarter of 2025.

[5] Intuitive FY2025 10-K（Stocklight副本）

发布日期：2026-02-03

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/06_source.txt

Total revenue $ 10,064.7 $ 8,352.1 $ 7,124.1

[7] Intuitive 2026Q2完整SEC 10-Q

发布日期：2026-07-21

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/q2_10q_secfull.txt

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Six Months Ended June 30, in millions 2026 2025 Operating activities: Net income $ 1,649.2 $ 1,367.9 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and loss on disposal of property, plant, and equipment 371.2 289.6 Amortization of intangible and other assets 59.9 24.4 Accretion of discounts, amortization of premiums, and (gains) losses on investments, net ( 19.0 ) ( 27.4 ) Gain on sale of business and assets ( 7.9 ) — Deferred income taxes 370.3 ( 29.4 ) Share-based compensation expense 419.4 381.4 Changes in operating assets and liabilities, net of effects of acquisitions: Accounts receivable ( 49.8 ) ( 44.1 ) Inventory ( 514.6 ) ( 494.2 ) Prepaids and other assets ( 179.0 ) ( 141.8 ) Accounts payable 21.4 72.4 Accrued compensation and employee benefits ( 229.7 ) ( 114.9 ) Deferred revenue 44.7 48.8 Other liabilities 36.8 ( 35.7 ) Net cash provided by operating activities 1,972.9 1,297.0 Investing activities: Purchase of investments ( 1,349.1 ) ( 691.8 ) Proceeds from sales of investments 0.1 249.1 Proceeds from maturities of investments 1,106.0 1,190.0 Proceeds from sale of assets 46.0 — Purchase of property, plant, and equipment ( 215.9 ) ( 271.9 ) Acquisition of business, net of cash, and intellectual property and other investing activities ( 528.2 ) ( 1.2 ) Net cash provided by (used in) investing activities ( 941.1 ) 474.2 Financing activities: Proceeds from issuance of common stock relating to employee stock plans 187.4 183.7 Taxes paid related to net share settlement of equity awards ( 365.4 ) ( 386.3 ) Repurchase of common stock ( 1,443.5 ) ( 181.0 ) Other financing activities ( 20.1 ) — Net cash used in financing activities ( 1,641.6 ) ( 383.6 ) Effect of exchange rate changes on cash, cash equivalents, and restricted cash 8.1 ( 3.5 ) Net increase (decrease) in cash, cash equivalents, and restricted cash ( 601.7 ) 1,384.1 Cash, cash equivalents, and restricted cash, beginning of period 3,407.4 2,062.4 Cash, cash equivalents, and restricted cash, end of period $ 2,805.7 $ 3,446.5 Supplemental and non-cash disclosures: Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment $ 419.3 $ 357.2 Acquisition of property, plant, and equipment in accounts payable and accrued liabilities 68.8 74.8 Unsettled common stock repurchases in accrued liabilities 63.5 —

[8] Intuitive欧洲da Vinci 5创新及Force Feedback CE标志公告

发布日期：2026-09-08

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/europe_20260908.txt

READING, UK, 8 September 2026 : Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the CE mark approval of Force Feedback instruments for its da Vinci 5 surgical system, as well as a series of new system enhancements to be rolled out across Europe. Force Feedback technology is designed to enhance intra-operative awareness of the force exerted on tissue during surgery, by enabling surgeons to feel push and pull forces through their da Vinci 5 console hand controls and measure these forces through a real time force indicator. Alongside Force Feedback instruments, Intuitive is introducing more than 100 updates and user experience enhancements for da Vinci 5 users in Europe. Powered by da Vinci 5's advanced computing architecture, which provides 10,000 times greater computing power than da Vinci Xi, these advancements represent the continued evolution of Intuitive's most advanced surgical system. "With the introduction of Force Feedback instruments and new capabilities for da Vinci 5 in Europe, we continue to deliver on our vision of a future-ready platform that can evolve with the needs of surgeons, patients and health systems," said Dirk Barten, Intuitive commercial president for Europe. "Across healthcare systems, our customers are challenged to deliver better patient outcomes, while also lowering the total cost of care, expanding access to care for more patients, and improving patient and care team experience. Through our portfolio of da Vinci systems and integrated Intuitive Ecosystem, shaped by over thirty years of expertise, we're continuing to help them meet those challenges."

[9] Intuitive公司新闻稿：良性病症荟萃分析（Finviz/GlobeNewswire转载）

发布日期：2026-09-08 16:05 ET

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/refresh_10.txt

The study analyzed data from more than 14 million da Vinci, laparoscopic and open procedures across 13 common benign (non-cancerous) conditions, making it the largest comparative meta-analysis of its kind. The authors found da Vinci surgery was associated with statistically significant improvements in select perioperative outcomes compared with laparoscopic and open surgery.

[10] Intuitive投资者活动页

发布日期：2026-09-09抓取；页面无单独发布日期

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/refresh_01.txt

Upcoming Events 07/16/26 - 1:30 PM PDT Q2 2026 INTUITIVE Earnings Conference Call [Listen to Webcast](https://edge.media-server.com/mmc/p/dekvotz4/)

[11] Intuitive 7月23日公司章程修订8-K

发布日期：2026-07-27

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/jul_8k.txt

On July 23, 2026, the Board of Directors of Intuitive Surgical, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”) to, among other things: i. allow the Company to disregard votes for any nominee made by a shareholder that do not comply with the universal proxy rules adopted by the U.S. Securities and Exchange Commission (“SEC”), including the requirement for shareholder proponents to solicit holders of 67% of outstanding shares; ii. clarify and enhance disclosures in connection with shareholder nominations of directors and submissions of proposals regarding other business at shareholder meetings, including by (a) refining disclosures of synthetic equity to utilize SEC-defined terms, (b) adding disclosures about the dates and intent of the shareholder’s investment, and (c) requiring the language of any bylaw amendments and information otherwise in the proxy statement; iii. clarify and enhance procedural mechanics and disclosure requirements in connection with shareholder nominations of directors and submissions of proposals regarding other business at shareholder meetings, including by (a) prohibiting nomination of more candidates than the number of directors up for election at the applicable meeting, (b) requiring that a shareholder be a record holder to request the required questionnaires for a nominee to complete, and (c) requiring the shareholder be present in person at the shareholder meeting; iv. require that any shareholder directly or indirectly soliciting proxies from other shareholders use a proxy card color other than white; v. provide logistics for shareholders to request a record date to determine who can call a special meeting of shareholders and require disclosures from the requesting shareholder similar to those for submitting nominations and proposals at an annual meeting of shareholders; vi. change the voting standard for corporate actions (other than elections) to a majority of votes cast (excluding abstentions and broker non-votes); and vii. make certain other technical amendments to conform to applicable law.

[12] ISRG Yahoo原始日线：2026-09-08完整交易日

发布日期：2026-09-08行情；2026-09-09抓取

证据文件：/mnt/q/private/stock_site/data/batches/20260909/market/ISRG-raw.json

"regularMarketPrice":350.16